Skip to main content
SpringerLink
Log in

Novel Anti-angiogenic Therapies in Ovarian Cancer

  • Chapter
  • First Online:
Emerging Therapeutic Targets in Ovarian Cancer

Abstract

The dawn of the new millennium heralded the era of novel biological agents in the treatment of advanced cancers. Foremost have been the anti-angiogenic compounds led by the confirmation of bevacizumab as a key component of front-line therapy in advanced colorectal cancer in 2004. Ovarian cancer is one of only a few solid tumours that responds to single-agent anti-VEGF therapy. VEGF inhibitors are also active when administered in combination with chemotherapy in a variety of settings including chemonaïve patients and in combination with metronomic chemotherapy for recurrent disease. This review focuses on the emergent data of new anti-angiogenic therapies in advanced ovarian cancer. We describe the developments to date, ongoing pivotal studies and critically appraise the role of novel anti-angiogenics in the treatment of ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Azad NS, Posadas EM, Kwitkowski VE, et al. (2008). Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–14.

    Article  PubMed  CAS  Google Scholar 

  • Biagi JJ, Oza AM, Grimshaw R, et al (2008). A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma – NCIC GTG IND 185. J Clin Oncol 26(Suppl):5522.

    Google Scholar 

  • Bidus A, Webb JC, Seidman JD, et al. (2006). Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 102:5–7.

    Article  PubMed  CAS  Google Scholar 

  • Browder T, Butterfield CE, Kraling BM, et al. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886.

    PubMed  CAS  Google Scholar 

  • Burger RA, Sill MW, Monk BJ, et al. (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165–71.

    Article  PubMed  CAS  Google Scholar 

  • Byrne AT, Ross L, Holash J, et al. (2003). Vascular endothelial growth factor trap decreases tumour burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721–28.

    PubMed  CAS  Google Scholar 

  • Campos SM, Dizon DS, Cannistra SA, et al. (2007). Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and Müllerian cancers. ASCO Meeting Abstracts Jun 20 2007: 5517.

    Google Scholar 

  • Cannistra SA, Matulonis UA, Penson RT, et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–86.

    Article  PubMed  CAS  Google Scholar 

  • Chan JK, Manuel MR, Chiaravino G, et al. (2006). Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol 103:919–23.

    Article  PubMed  CAS  Google Scholar 

  • Chura JC, Van Iseghem K, Downs LS, et al. (2007). Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107:326–30.

    Article  PubMed  CAS  Google Scholar 

  • Cohn DE, Valmadre S, Resnick KE, et al. (2006). Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102:134–39.

    Article  PubMed  CAS  Google Scholar 

  • Coleman RL, Broaddus RR, Bodurka DC, et al. (2006). Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1):126–31.

    Article  PubMed  CAS  Google Scholar 

  • Coleman RL, Kamat A, Iyer R, et al. (2009). Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol 27(15s):(suppl; abstr 5549).

    Google Scholar 

  • Downs LS Jr, Judson PL, Argenta PA, et al. (2007). A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 112:331–39.

    Article  CAS  Google Scholar 

  • Escudier B, Eisen T, Stadler WM, et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–34.

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438:967–74.

    Article  PubMed  CAS  Google Scholar 

  • Folkman J (1990). What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6.

    Article  PubMed  CAS  Google Scholar 

  • Friedlander M, Hancock KC, Benigno B, et al. (2007). Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J Clin Oncol 25(Suppl):5561.

    Google Scholar 

  • Fukumura D, Jain RK (2007). Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101:937–49.

    Article  PubMed  CAS  Google Scholar 

  • Gaducci A, Ferrero A, Cosio S, et al. (2006). Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res 26:3925–32.

    Google Scholar 

  • Garcia AA, Hirte H, Fleming G, et al. (2008). Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26:76–82.

    Article  PubMed  CAS  Google Scholar 

  • Goede V, Schmidt T, Kimmina S, et al. (1998). Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78:1385–94.

    PubMed  CAS  Google Scholar 

  • Gridelli C, Rossi A, Maione P, et al. (2009). Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612–20.

    Article  PubMed  CAS  Google Scholar 

  • Hamilton CA, Maxwell GL, Chernofsky MR, et al. (2008 Dec). Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111(3):530–32.

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Bergers G, Bergsland E (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–47.

    Article  PubMed  CAS  Google Scholar 

  • Hans ES, Monk BJ (2007). What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105:3–6.

    Article  CAS  Google Scholar 

  • Hapani S, Chu D, Wu S (2009). Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–68.

    Article  PubMed  CAS  Google Scholar 

  • Hasan J, Byers R, Jayson GC (2002). Intratumoral microvessel density in human solid tumours. Br J Cancer 86:1566–77.

    Article  PubMed  CAS  Google Scholar 

  • Hecht JR, Mitchell E, Chidiac T, et al. (2009). A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27(5):672–80.

    Article  PubMed  CAS  Google Scholar 

  • Hefler LA, Mustea A, Konsgen D, et al. (2007). Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13:898–901.

    Article  PubMed  CAS  Google Scholar 

  • Herbst RS, Hong D, Chap L, et al. (2009). Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557–65.

    Article  PubMed  CAS  Google Scholar 

  • Hillen F, Griffioen AW (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Met Rev 26:489–502.

    Article  Google Scholar 

  • Hirte HW, Vidal L, Fleming GF, et al. (2008). A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California Consortia Trial. J Clin Oncol 26:May 20 suppl; abstr 5521.

    Google Scholar 

  • Hu L, Hofmann J, Zaloudek C, Ferrara N, et al. (2002). Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161(5):1917–24.

    PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–42.

    Article  PubMed  CAS  Google Scholar 

  • Jayson GC, Parker GJ, Mullamitha S et al. (2005). Blockade of platelet-derived growth factor receptor-beta by CDP860 a humanized PEGylated di-Fab leads to fluid accumulation and is associated with increased tumour vascularised volume. J Clin Oncol 23:973–981.

    Google Scholar 

  • Jemal A, Siegel R, Ward E, et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96.

    Article  PubMed  Google Scholar 

  • Je Y, Schutz FA, Choueiri TK (2009). Risk of bleeding with vascular endothelial growth factor receptor tyrosine kinase inhibitors sunitinib and sorafenib: a systematic review and meta analysis of clinical trials. Lancet Oncol 10:967–974.

    Google Scholar 

  • Jurado JM, Sánchez A, Pajares B, et al. (2008). Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 10:583–86.

    Article  PubMed  CAS  Google Scholar 

  • Kamat AA, Kim TJ, Landen CN Jr, et al. (2007). Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67:281–88.

    Article  PubMed  CAS  Google Scholar 

  • Kelly CJ, Mir FA (2009). Biological therapies: how can we afford them. BMJ 339:b3276.

    Article  PubMed  Google Scholar 

  • Kikuchi Y, Kouta H, Kikuchi R, et al. (2009). Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer. J Clin Oncol 27(15s):(suppl; abstr 5547).

    Google Scholar 

  • Klement G, Baruchel S, Rak J, et al. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24.

    Article  PubMed  CAS  Google Scholar 

  • Konner JA, Grabon D, Pezzulli S, et al. (2009). A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovary, primary peritoneal and fallopian tube cancers. J Clin Oncol 27(15s):(suppl; abstr 5539).

    Google Scholar 

  • Kumaran GC, Jayson GC, Clamp AR (2009). Antiangiogenic drugs in ovarian cancer. Br J Cancer 100:1–7.

    Article  PubMed  CAS  Google Scholar 

  • Landen CN, Kinch MS, Sood AK (2005). EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 9:1179–85.

    Article  PubMed  CAS  Google Scholar 

  • Langberg M, van Herpen CM, De Bono JS, et al. (2008). Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. J Clin Oncol 26:May 20 suppl; abstr 3555.

    Google Scholar 

  • Ledermann JA, Rustin GJ, Kackshaw A, et al. (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 27(15s):(suppl; abstr 5501).

    Google Scholar 

  • Lee JW, Han HD, Shahzad MM, et al. (2009). EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl cancer Inst 101:1193–205.

    Article  PubMed  CAS  Google Scholar 

  • Llovet J, Ricci S, Mazzaferro V, et al. (2007). Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomised placebo-controlled trial (SHARP trial). J Clin Oncol ASCO 25:18S.

    Google Scholar 

  • Mabuchi S, Terai Y, Morishige K, et al. (2008). Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 14(23):7781–89.

    Article  PubMed  CAS  Google Scholar 

  • Maitland ML, Moshier K, Imperial J, et al. (2006). Blood pressure as a biomarker for sorafenib, an inhibitor of the VEGF signaling pathway. J Clin Oncol 24(87s):(suppl; abstr 2035).

    Google Scholar 

  • Mandrekar SJ, Sargent DJ (2009). Clinical trial design for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:4027–34.

    Article  PubMed  Google Scholar 

  • Matei D, Sill MW, De Geest K, Bristow RE (2008). Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) Study. J Clin Oncol 26(Suppl):5537.

    Google Scholar 

  • Matulonis UA, Berlin ST, Krasner CN, et al. (2008). Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 26(Suppl):5501.

    Google Scholar 

  • McMeekin DD, Lanneau G, Curiel J, et al. (2009). II or III ovarian, primary peritoneal, and fallopian tube cancer. Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers. Clin Oncol 27(15s):(suppl; abstr 5540).

    Google Scholar 

  • Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. (2005). Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24(6):1053–65.

    Article  PubMed  CAS  Google Scholar 

  • Mesiano S, Ferrara N, Jaffe RB (1998). Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153(4):1249–56.

    PubMed  CAS  Google Scholar 

  • Micha JP, Goldstein BH, Rettenmaier MA, et al. (2007). A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771–76.

    Article  PubMed  CAS  Google Scholar 

  • Miller K, Wang M, Gralow J, et al. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  • Mir O, Ropert S, Alexandre J, Goldwasser F (2009). Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20:967–70.

    Article  PubMed  CAS  Google Scholar 

  • Monk BJ, Han E, Josephs-Cowan CA, et al. (2006). Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102(2):140–44.

    Article  PubMed  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–24.

    Article  PubMed  CAS  Google Scholar 

  • Muggia FM, Boyd L, Liebes L, et al. (2009). Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 27(15s):(suppl; abstr 5548).

    Google Scholar 

  • Nimeiri HS, Oza AM, Morgan RJ, et al. (2008). Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49–55.

    Article  PubMed  CAS  Google Scholar 

  • Olson TA, Mohanraj D, Carson LF, et al. (1994). Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276–80.

    PubMed  CAS  Google Scholar 

  • Osada R, Horiuchi A, Kikuchi N, et al. (2006). Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and allelic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37:1414–25.

    Article  PubMed  CAS  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108.

    Article  PubMed  Google Scholar 

  • Posadas EM, Kwitkowski V, Kotz HL, et al. (2007). A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110(2):309–17.

    Article  PubMed  CAS  Google Scholar 

  • Ramakrishnan S, Subramanian I, Yokoyama Y, et al. (2005). Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8:169–82.

    Article  PubMed  CAS  Google Scholar 

  • Ricart AD, Tolcher AW, Liu G, et al. (2008). Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I pharmacokinetic and biological correlative study. Clin Cancer Res 14:7924–7929.

    Google Scholar 

  • Richardson DL, Backes FJ, Seamon LG, et al. (2008). Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111:461–66.

    Article  PubMed  CAS  Google Scholar 

  • Rubatt JM, Darcy KM, Hutson A, et al. (2009). Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecology Oncology Group Study. Gynecol Oncol 112:469–74.

    Article  PubMed  CAS  Google Scholar 

  • Sandler AB, Gray R, Perry MC, et al. (2006). Paclitaxel–carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542–50.

    Article  PubMed  CAS  Google Scholar 

  • Sargent DJ, Wieand HS, Haller DG, et al. (2005). Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–70.

    Article  PubMed  Google Scholar 

  • Schroder W, Campone M, Abadie S, et al. (2006). A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). J Clin Oncol. 24(18S):(June 20 Supplement): 5075.ASCO Annual Meeting Proceedings Part I.

    Google Scholar 

  • Schultheis AM, Lurje G, Rhodes KE, et al. (2008). Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554–63.

    Article  PubMed  CAS  Google Scholar 

  • Semenza GL (1998). Hypoxia-inducible factor-1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588–94.

    Article  PubMed  CAS  Google Scholar 

  • Sfakanios GP, Numnum TM, Halverson CB, et al. (2009). The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol 114:424–26.

    Article  CAS  Google Scholar 

  • Shen GH, Ghazizadeh M, Kawanami O, et al. (2000). Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196–203.

    Article  PubMed  CAS  Google Scholar 

  • Spannuth WA, Sood AK, Coleman RA (2008). Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5:194–204.

    Article  PubMed  CAS  Google Scholar 

  • Tao X, Sood AK, Deavers MT, et al. (2009). Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114:431–36.

    Article  PubMed  CAS  Google Scholar 

  • Tew WP, Colombo N, Ray-Coquard I, et al. (2007). VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25(Suppl):5508.

    Google Scholar 

  • Veronese ML, Mosenkis A, Flaherty KT, et al. (2006). Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363–69.

    Article  PubMed  CAS  Google Scholar 

  • Wright JD, Secord AA, Numnum TM, et al. (2008). A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 18:400–6.

    Article  PubMed  CAS  Google Scholar 

  • Yang JC, Haworth L, Sherry RM, et al. (2003). A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–34.

    Article  PubMed  CAS  Google Scholar 

  • Zhu X, Wu S, Dahut W, et al. (2007). Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186–93.

    Article  PubMed  CAS  Google Scholar 

  • Zweifel M, Jayson G, Reed N, et al. (2009). Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results. J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 27(15S):5502.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Christie Hospital, Manchester, UK

    Jurjees Hasan & Gordon Jayson

Authors
  1. Jurjees Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon Jayson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jurjees Hasan .

Editor information

Editors and Affiliations

  1. Royal Marsden Hospital, Drug Development Unit, Institute of Cancer Research, Sutton, SM2 5PT, United Kingdom

    Stan Kaye

  2. , Department of Surgery and Cancer, Imperial College London, London, W12 0NN, United Kingdom

    Robert Brown

  3. , Department of Surgery and Cancer, Imperial College, London, W12 0NN, United Kingdom

    Hani Gabra

  4. , Department of Medicine, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom

    Martin Gore

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hasan, J., Jayson, G. (2011). Novel Anti-angiogenic Therapies in Ovarian Cancer. In: Kaye, S., Brown, R., Gabra, H., Gore, M. (eds) Emerging Therapeutic Targets in Ovarian Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7216-3_3

Download citation

Publish with us

Policies and ethics

Search

Navigation